Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
13 p, 2.0 MB Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer / Garrido-Castro, Ana (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ; Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ; Guo, Hao (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Data Sciences) ; Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ; Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ; Gavilá, Joaquin (Fundació Institut Valencià d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré Brunet, Laia (SOLTI Breast Cancer Research Group) ; Céliz, Pamela (SOLTI Breast Cancer Research Group) ; Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ; Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ; Savoie, Jennifer (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Xu, Zhan (Northern Arizona University. School of Communication) ; Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ; Krop, Ian E. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Solit, David B. (Memorial Sloan Kettering Cancer Center) ; Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ; Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ; Winer, Eric P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Lin, Nancy U. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ; Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)  
2.
10 p, 889.8 KB Predicting response and survival in chemotherapy-treated triple-negative breast cancer / Prat, A. (Universitat Autònoma de Barcelona. Departament de Medicina) ; Lluch, Ana (Hospital Clínic Universitari (València)) ; Albanell Mestres, Joan (Universitat Pompeu Fabra) ; Barry, W. T. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Biostatistics and Computational Biology) ; Fan, C. (University of North Carolina. Lineberger Comprehensive Cancer Center) ; Chacón, José Ignacio (Hospital Virgen de la Salud (Toledo)) ; Parker, J. S. (University of North Carolina. Department of Genetics) ; Calvo, L.. (Complejo Hospitalario Universitario de A Coruña) ; Plazaola, A. (Department of Medical Oncology, Onkologikoa) ; Arcusa, Àngels (Consorci Sanitari de Terrassa. Departament d'Oncologia Mèdica) ; Seguí-Palmer, M. A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Burgués, Octavio (Hospital Clínic Universitari (València)) ; Ribelles, Nuria (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Rodriguez-Lescure, A. (Hospital General Universitario de Elche) ; Guerrero, A. (Fundació Institut Valencià d'Oncologia) ; Ruiz-Borrego, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Munárriz, Blanca (Hospital Universitari i Politècnic La Fe (València)) ; López, J. A. (Hospital San Camilo) ; Adamo, Barbara (Hospital Universitari Vall d'Hebron) ; Cheang, M. C. U. (University of North Carolina. Lineberger Comprehensive Cancer Center) ; Li, Y (University of North Carolina. Lineberger Comprehensive Cancer Center) ; Hu, Z. (University of North Carolina. Lineberger Comprehensive Cancer Center) ; Gulley, M. L. (University of North Carolina. Lineberger Comprehensive Cancer Center) ; Vidal, M. J. (Hospital Universitari Vall d'Hebron) ; Pitcher, B. N. (Alliance Statistical and Data Center, Duke University) ; Liu, M. C. (Mayo Clinic. Department of Oncology) ; Citron, M. L. (ProHEALTH Care Associates, LLP) ; Ellis, M. J. (Washington University. Department of Oncology) ; Mardis, E. (Washington University. Department of Oncology) ; Vickery, T. (Washington University. Department of Oncology) ; Hudis, C. A. (Memorial Sloan Kettering Cancer Center) ; Winer, E. P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Carey, L. A. (University of North Carolina. Lineberger Comprehensive Cancer Center) ; Caballero, Rosalía (Grupo Español de Investigación en Cáncer de Mama) ; Carrasco, E. (Grupo Español de Investigación en Cáncer de Mama) ; Martín, M. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ; Perou, Charles M. (University of North Carolina. Department of Pathology and Laboratory Medicine) ; Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. [...]
2014 - 10.1038/bjc.2014.444
British Journal of Cancer, Vol. 111 (08 2014) , p. 1532-1541  

Vegeu també: autors amb noms similars
1 Winer, E. P.
1 Winer, Eric P.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.